Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
When combined, the inhibition of NF-B or p38 MAPK may impact ROS/RNS production and reduce the generation of cytokines in patients with IBD, particularly when the disease is actively progressing ( Figure 4 Similarly, combining TLR4/NF-B and Nrf2-ARE pathway modulation offers a comprehensive approach to managing IBD by simultaneously reducing inflammation and enhancing antioxidant defenses
Available in Australia: Yes 41
EMBO J 2002, 21: 4229-4239
Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, et al
US$ 20.32
US$ 26.33
US$ 28.43
